๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B Cell Lymphoma (DLBCL)
Clinical trial register · China

Diffuse Large B Cell Lymphoma (DLBCL) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 7 Beijing 6 Hangzhou 5 Fuzhou 3 Harbin 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou7 Beijing6 Hangzhou5 Fuzhou3 Harbin3
All 28 locations
Target enrolment
to

Diffuse Large B Cell Lymphoma (DLBCL) trials in China

28 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7ร—19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
NCT07788118Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transforming Follicular Lymphoma (tFL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
70
Hangzhou
2026-09-01
Not yet open
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588Diffuse Large B-Cell Lymphoma (DLBCL)
Dizal Pharmaceuticals
Phase 2/3
880
Chongqing, Harbin, Changsha, Jinan, Shanghai
2026-09
Not yet open
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07599423Diffuse Large B Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University
Phase 2
96
Suzhou
2026-07-22
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
NCT07609862Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenstrรถm Macroglobulinemia (WM)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2
92
Tianjin
2026-07-14
Not yet open
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07669194Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
30
Hangzhou
2026-06-10
Recruiting
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
NCT07493109Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD
Phase 3
200
Changchun
2026-05-30
Recruiting
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
NCT07493148Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD
Phase 2
50
Changchun
2026-04-30
Recruiting
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
NCT07523737Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)
Beijing Tongren Hospital
Phase 2
43
Beijing
2026-04-01
Recruiting
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
NCT07494565Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
Sun Yat-sen University
Phase 2
60
Guangzhou
2026-03-06
Not yet open
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
NCT07398638Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 1/2
122
Guangzhou
2026-02-28
Recruiting
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT07397832Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
58
Tianjin
2026-02-03
Recruiting
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
NCT07499271Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University
Phase 2
35
Suzhou
2026-01-01
Not yet open
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
NCT07168291Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1
3
Xi'an
2025-12-31
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
NCT07371923Diffuse Large B Cell Lymphoma (DLBCL)
Beijing Tongren Hospital
Phase 2
50
Beijing
2025-11-20
Recruiting
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
NCT07084662Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2/3
80
Guangzhou
2025-09-11
Recruiting
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07260812Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
TCRx Therapeutics Co.Ltd
Phase 1
18
Wuhan
2025-09-01
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
NCT07078500Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2025-05-05
Recruiting
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
NCT06682130Diffuse Large B-cell Lymphoma(DLBCL)
The First Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2024-11-10
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Not yet open
Molecular Subtype-Guided R-CHOP-MTXยฑZanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432Diffuse Large B Cell Lymphoma (DLBCL)
DrugR-Chop
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2024-10
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT06464861Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
52
Hangzhou
2024-06-20
Active, closed
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT05563844Diffuse Large B Cell Lymphoma๏ผŒDLBCL
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
74
Shanghai, Chengdu
2022-11-08
Recruiting
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/diffuse-large-b-cell-lymphoma-dlbcl

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies listing the condition Diffuse Large B Cell Lymphoma (DLBCL).

How many Diffuse Large B Cell Lymphoma (DLBCL) trials are recruiting in China?

19 of the 28 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B Cell Lymphoma (DLBCL)), 28 studies
PhaseStudiesRecruitingShare
Phase 2151253.6%
Phase 1/25317.9%
Observational207.1%
Phase 1227.1%
Phase 2/3217.1%
Phase 3113.6%
Phase EARLY_PHASE1103.6%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B Cell Lymphoma (DLBCL))
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine43
Sun Yat-sen University43
The First Affiliated Hospital of Soochow University32
Beijing Tongren Hospital22
Guangzhou Lupeng Pharmaceutical Company LTD.22
Ou Bai, MD/PHD22
The First Affiliated Hospital with Nanjing Medical University21
Chengdu Zenitar Biomedical Technology Co., Ltd10
Dizal Pharmaceuticals10
First Affiliated Hospital Xi'an Jiaotong University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.